Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3835 | cleavage-stage embryo transfer Wiki | 0.38 |
| drug1398 | Generalized Anxiety Disorder-7 (GAD-7) Wiki | 0.38 |
| drug1259 | Exposure: Covid-19 infection Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007247 | Infertility, Female NIH | 0.38 |
| D007248 | Infertility, Male NIH | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000789 | Infertility HPO | 1.00 |
| HP:0003251 | Male infertility HPO | 0.38 |
| HP:0008222 | Female infertility HPO | 0.38 |
Navigate: Correlations HPO
There are 7 clinical trials
The aim of this RCT is to compare differences in the efficacy and safety between cleavage-stage embryo transfer and blastocyst-stage embryo transfer in IVF/ICSI treatment cycle, taking into account of subsequent vitrified embryo transfers. Subjects with 3 or more transferrable cleavage embryos will be randomized to the cleavage-stage or blastocyst-stage embryos transfer group. The primary outcome is cumulative live birth rate (CLBR) per patient until the first live birth from one initiated oocyte retrieval cycle, calculated using outcomes from the first three embryo transfers within 1 year after randomization.
Description: Cumulative live birth rate (CLBR) is defined the first live birth per patient from one initiated oocyte retrieval cycle(Calculated using outcomes from the first three embryo transfers within 1 year after randomization). Live birth is defined as delivery of any neonate ≥24 weeks gestation with heart beat and breath.
Measure: cumulative live birth rate Time: 30 monthsDescription: Biochemical pregnancy is defined as a serum β-HCG level of at least 25 IU/L 14 days after embryo transfer.
Measure: biochemical pregnancy rate Time: 30 monthsDescription: Clinical pregnancy is defined by the presence of intrauterine gestation sacs at 30-35 days after embryo transfer.
Measure: clinical pregnancy rate Time: 30 monthsDescription: Ongoing pregnancy is defined as a viable pregnancy at 12 weeks gestation.
Measure: ongoing pregnancy rate Time: 30 monthsDescription: Pregnancy loss is defined as a pregnancy that results in a spontaneous abortion or therapeutic abortion that occurred throughout pregnancy.
Measure: Pregnancy loss rate Time: 30 monthsDescription: Number of patients with moderate or severe OHSS/ number of COS cycles.
Measure: moderate or severe OHSS rate Time: 12 monthsDescription: diagnosed by ultrasound examination or laparoscopic surgery visualizing more than or equal to 1 gestational sacs outside the uterus or by abnormally increasing serum hCG level without sonographic visualization and the absence of chorionic villi inside the uterus after uterine curettage, which was treated by methotrexate.
Measure: ectopic pregnancy Time: 24 monthsDescription: the ratio of males to females in the newborns
Measure: sex ratio Time: 30 monthsDescription: Number of multiple pregnancies / number of clinical pregnancies.
Measure: multiple pregnancy Time: 30 monthsDescription: Number of pregnancies with complications / number of pregnancies; ;number of live births with neonatal complications / number of live births
Measure: incidence of obstetric and perinatal complications Time: 30 monthsDescription: structural or functional anomalies that occur during intrauterine life and can be identified prenatally, at birth or later in life.
Measure: congenital anomalies Time: 30 monthsDescription: the number of gestational sacs detected with sonography at 6 weeks of pregnancy/the number of embryos transferred
Measure: implantation rate Time: 30 monthsDescription: Weight of newborns at delivery
Measure: Birth weight Time: 30 monthsInfertility is a severely distressing experience for many couples. Depression and anxiety are psychological disorders associated with infertility, and they may worsen during infertility treatments. This study times to understand the changes in the psychological status of infertile patients who had in vitro fertilization (IVF) treatment interrupted or postponed because of the COVID-19 pandemic.
The COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.
Description: Sperm concentration (x10^6/ml) between case and control group.
Measure: Semen parameters Time: 3 visits (up to 75 days apart)Description: Sperm Motility (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Sperm normal morphology (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Testosterone (nmol/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Follicle Stimulating Hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Luteinising hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.
Measure: Seminal Reactive oxygen species Time: 3 visits (up to 75 days apart)Description: Compare Sperm DNA fragmentation rate (%) between case and control group.
Measure: Sperm DNA fragmentation rate Time: 3 visits (up to 75 days apart)Recently, the world was shaken awake by a pandemic caused by a novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). In most nations drastic isolation measures were taken to minimize the further spread of the Coronavirus Disease 2019 (COVID-19). Being the first pandemic sparked by a Coronavirus, little was known on COVID-19 and its implications on general health. Our understanding on the virus and its potential effects on health is growing. In Belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. As also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. The limited evidence of SARS-CoV-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active SARS-CoV-2 infection on female gametes. Viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out. Since the onset of the pandemic, knowledge about the molecular details of SARS-CoV-2 infection rapidly grew. Coronaviruses are enveloped RNA viruses. For a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. The coronavirus surface protein spike (S) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. The SARS-CoV-2-S protein (SARS-S) utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry. Host proteases such as transmembrane serine protease 2 (TMPRSS2) are then needed to cleave the viral S protein, allow-ing permanent fusion of the viral and host cell membranes2. Expression of ACE2 and TMPRSS2 has been shown in testicular, uterine and placental cells. Based on available transcriptomic data, co-expression of ACE2 and TMPRSS2 is also seen on oocyte level, but the possible impact on reproduction is unknown. The BSG (basigin or CD147), a receptor on host cells, was also identified as a possible route for viral invasion.
Description: Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval
Measure: Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium Time: 1 dayDescription: Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2
Measure: Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium Time: 1 dayNon-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility. This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .
Description: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey
Measure: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation Time: 1 dayDescription: . Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy
Measure: Risk assessment Time: 1 dayDescription: Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey
Measure: Patients'expectations regarding the management of an abrupt closure of the fertility center Time: 1 dayIn France, one couple in eight encounters difficulties to conceive. The diagnosis of infertility frequently leads to symptoms of anxiety and depression. These symptoms appear to be higher than in the general population. Some recent studies have looked at the relationship between anxiety and depression in ART cares. Results are controversial, but it appears that patients with lower levels of anxiety and depression have higher pregnancy rates. Moreover, in couple, women seem to have more symptoms of anxiety and depression than men. First epidemiological studies related to the COVID 19 pandemic have shown strong psychological impact on the general population with an anxiety rate estimated at more than 30%. With COVID 19 pandemic and cessation of ART, it is highly likely that psychic symptoms of anxiety or even depression may have appeared or worsened in women undergoing infertility treatment.
Description: Perceived Stress Scale 10 assess stress in 10 questions with score from 0 to 40. The higher the score is, the more important the stress level is.
Measure: Psychological impact assessed by scores of PSS10 scales. Time: 15 minutesDescription: depression Scale with 14 questions. It assesses separately anxiety (score from 0 to 21) and depression (score from 0 to 21).The higher the score is, the more important the anxiety level is.
Measure: Psychological impact assessed by scores of HADS scales. Time: 15 minutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports